Prior to RTX administration, general clinical parameters including gender, age, blood pressure, previous treatment regimens, and current combination therapies were collected. At subsequent 3 months intervals after RTX administration, laboratory variables related with nephrotic syndrome and renal function were collected.
Anti-PLA2R antibodies were detected using a commercial enzyme-linked immunosorbent assay (ELISA) kit (EUROIMMUN AG, Lübeck, Germany). Blood urea nitrogen (BUN), and serum albumin were measured by colorimetry using Cobas c 701 (Roche, Basel, Switzerland). Serum creatinine was measured by Enzymatic methods using Cobas c 701 (Roche, Basel, Switzerland). The amount of proteinuria was evaluated by 24-h urine protein. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney disease Epidemiology Collaboration (CKD-EPI) formula.